CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Palo Alto, California, United States and 47 other locations
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...
Phase 2, Phase 3
Palo Alto, California, United States and 7 other locations
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...
Phase 1
Palo Alto, California, United States and 8 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Palo Alto, California, United States and 33 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
San Francisco, California, United States and 22 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Palo Alto, California, United States and 13 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Oakland, California, United States and 43 other locations
chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...
Phase 2
Palo Alto, California, United States and 8 other locations
with relapsed or refractory B-cell acute lymphoblastic leukemia with high bone marrow lymphoblast percentage (\>50% lymphoblasts)....
Phase 1, Phase 2
San Francisco, California, United States and 3 other locations
in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related a....
Phase 2
San Francisco, California, United States and 3 other locations
Clinical trials
Research sites
Resources
Legal